Prostate cancer

Prostate cancer
2025-11-21T00:00:00.000+11:00
Ongoing

ATNM-400-1301

ATNM-400-1301
Genitourinary (GU)

Phase 1 Trial of a Novel HER3 Antibody Targeted Radiotherapy in Patients with Metastatic Castrate-Resistant Prostate Cancer.

A phase 1 Trial of a Novel HER3 Antibody Targeted Radiotherapy in Patients with Metastatic Castrate-Resistant Prostate Cancer.

Trial overview

Clinical Area

Theranostics

Disease

Prostate

Disease site

Genitourinary (GU)

Study Phase

Phase I

Trial Identifiers

Registration number: CT-2025-CTN-04756-1

GenesisCare Location(s)
Principal Investigator(s)
Nuclear Medicine Physician

Prof. Joe Cardaci

MBBS, FRACP, AANNMS

Prof. Joe Cardaci
Joe
Cardaci
location pin icon
View Profile
Profile Image - Prof. Joe Cardaci

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.